Real-World Experience With Secukinumab for Hidradenitis Suppurativa: A Multicenter Retrospective Analysis of 263 Patients From the SECU-SPAIN Study
Year: 2025
Type: article
Study design: Observational Study
Abstract: BACKGROUND/OBJECTIVE: There is no consensus on the response rates of secukinumab, as findings from phase III trials differ from those reported in clinical-practice studies. This study aimed to assess the mid-term safety and efficacy profile of secukinumab in patients with moderate-to-severe Hidradenitis suppurativa (HS). METHODS: This retrospective, multicenter study included patients with moderate-to-severe HS treated with secukinumab (300mg every four weeks) between 2020 and 2024. Eligible patients were aged ≥18 years, with a clinical diagnosis of moderate-to-severe HS, and a minimum follow-up of 24 weeks. Key exclusions included patients treated with nonstandard secukinumab dosing regimens or those with insufficient clinical data. The primary endpoints were achievement of HiSCR50 (≥50% reduction in the combined count of nodules and abscesses) at weeks 16 and 24). Secondary endpoints included achieving a ≥55% reduction in the International HS Severity Score (IHS4-55) and adverse events. RESULTS: A total of 263 patients (49.4%, women; 50.6%, men; mean age, 41.8±13.2 years) were included. The most common HS phenotype was mixed (49.4%), and 55.1% had Hurley stage III disease. At weeks 16 and 24, a total of 57.4% and 63.6% of patients achieved HiSCR50, respectively. The mean IHS4 score dropped significantly from 16.7±10.0 at baseline to 7.6±5.6 at week 24 (p<0.0001). At weeks 16 and 24, 52% and 56% of patients achieved an IHS4-55 response. Secukinumab was discontinued in 14.5% of patients because of lack of efficacy or adverse events. CONCLUSIONS: Secukinumab demonstrated a significant safety and efficacy profile for patients with moderate-to-severe in a real-world setting, with better outcomes than those reported in earlier clinical trials. Response evaluation at both week 16 and 24 is crucial due to variations in treatment effectiveness.
Source: Actas Dermo-Sifiliográficas
Authors: A. Martorell, E. Vilarrasa-Rull, P. Fernandez-Crehuet, A. Molina-Leyva, M. Mansila-Polo, R. Garcia-Ruiz, P. Garbayo-Salmons, J.M. Ortiz-Salvador, F. Alfageme-Roldan, J. Garcias-Ladaria, J. Bassas-Vila, I. Fuertes-de-Vega, L. Carnero-Gonzalez, M. Almenara-Blasco, I. Torres-Navarro, R. Aguayo-Ortiz, P. Gil Pallares, R. Fornons-Servent, I. Gracia-Darder, V. Mora-Fernández, O. Corral, L. Pericet-Fernandez, F. Navarro, S. Haselgruber, G. Ochando-Ibernon, A. Menéndez-Parron, E. Masferrer, M. Gamissans, M. Solera-Talamante, M. Moya, A. Imbernon, J. Melgosa
Institutions: Hospital de Manises, Hospital de Sant Pau, Hospital Universitario Reina Sofía, Hospital Universitario Virgen de las Nieves, Hospital Universitari i Politècnic La Fe, Hospital Universitario Doctor Peset, Corporació Sanitària Parc Taulí, Hospital General Universitario De Valencia, Hospital Universitario Puerta de Hierro Majadahonda, Hospital Universitario Son Espases, Hospital Universitari Germans Trias i Pujol, Hospital Clínic de Barcelona, Hospital Universitario Miguel Servet, Hospital de Sagunto, Hospital Universitari Arnau de Vilanova, Bellvitge University Hospital, Hospital Universitario Lluís Alcanyís, Hospital Universitario Severo Ochoa
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,080
OpenAlex ID: W4417290104